20 related articles for article (PubMed ID: 12381362)
1. Perspective: A proposal on solutions of modern supply chain construction for lactoferrin.
Mao R; Ma X; Hao Y; Pen G; Zheng X; Yang N; Teng D; Wang J
J Dairy Sci; 2023 Nov; 106(11):7329-7335. PubMed ID: 37641347
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticular and other carriers to deliver lactoferrin for antimicrobial, antibiofilm and bone-regenerating effects: a review.
Ong R; Cornish J; Wen J
Biometals; 2023 Jun; 36(3):709-727. PubMed ID: 36512300
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput method for the quantification of iron saturation in lactoferrin preparations.
Majka G; Śpiewak K; Kurpiewska K; Heczko P; Stochel G; Strus M; Brindell M
Anal Bioanal Chem; 2013 Jun; 405(15):5191-200. PubMed ID: 23604471
[TBL] [Abstract][Full Text] [Related]
4. Cattle mammary bioreactor generated by a novel procedure of transgenic cloning for large-scale production of functional human lactoferrin.
Yang P; Wang J; Gong G; Sun X; Zhang R; Du Z; Liu Y; Li R; Ding F; Tang B; Dai Y; Li N
PLoS One; 2008; 3(10):e3453. PubMed ID: 18941633
[TBL] [Abstract][Full Text] [Related]
5. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis.
van Berkel PH; Geerts ME; van Veen HA; Kooiman PM; Pieper FR; de Boer HA; Nuijens JH
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):107-14. PubMed ID: 7492299
[TBL] [Abstract][Full Text] [Related]
6. Characterization of recombinant human lactoferrin secreted in milk of transgenic mice.
Nuijens JH; van Berkel PH; Geerts ME; Hartevelt PP; de Boer HA; van Veen HA; Pieper FR
J Biol Chem; 1997 Mar; 272(13):8802-7. PubMed ID: 9079716
[TBL] [Abstract][Full Text] [Related]
7. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide.
Elass-Rochard E; Roseanu A; Legrand D; Trif M; Salmon V; Motas C; Montreuil J; Spik G
Biochem J; 1995 Dec; 312 ( Pt 3)(Pt 3):839-45. PubMed ID: 8554529
[TBL] [Abstract][Full Text] [Related]
8. The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells.
Legrand D; van Berkel PH; Salmon V; van Veen HA; Slomianny MC; Nuijens JH; Spik G
Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):841-6. PubMed ID: 9581564
[TBL] [Abstract][Full Text] [Related]
9. Rapid purification of porcine colostral whey lactoferrin by affinity chromatography on single-stranded DNA-agarose. Characterization, amino acid composition and N-terminal amino acid sequence.
Hutchens TW; Magnuson JS; Yip TT
Biochim Biophys Acta; 1989 Dec; 999(3):323-9. PubMed ID: 2605266
[TBL] [Abstract][Full Text] [Related]
10. Structure and biological actions of lactoferrin.
Nuijens JH; van Berkel PH; Schanbacher FL
J Mammary Gland Biol Neoplasia; 1996 Jul; 1(3):285-95. PubMed ID: 10887502
[TBL] [Abstract][Full Text] [Related]
11. Analytical cation-exchange chromatography to assess the identity, purity, and N-terminal integrity of human lactoferrin.
van Veen HA; Geerts ME; van Berkel PH; Nuijens JH
Anal Biochem; 2002 Oct; 309(1):60-6. PubMed ID: 12381362
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
